AI & the Future of Genetic Testing: Ezra Cohen, CMO of Tempus

This is a free preview of a paid episode. To hear more, visit www.mendelspod.com

As 2025 begins, we are launching a new series The New Genetic Testing. To do that we’re welcoming today Dr. Ezra Cohen, Chief Medical Officer at Tempus to offer a behind-the-scenes look at how the company is transforming healthcare through cutting-edge AI. With its recent successful IPO, Tempus has firmly established itself as a leader in genomic testing and multimodal data integration and empowering providers and life sciences companies to make better decisions for patients.

"Tempus is really a tech company applying sophisticated AI to the healthcare space," explains Dr. Cohen. With tools like TempusOne, an AI-powered assistant, oncologists and other clinicians can access real-time insights, from interpreting genetic tests to exploring treatment options and clinical trials.”

Dr. Cohen highlights Tempus’ unique approach to data collection, amassing 300 petabytes of multimodal data—50 times larger than the largest public oncology database. This vast resource, paired with advanced AI, allows Tempus to provide unparalleled context for each patient.

"We’re not just saying this cancer has this gene mutated. We’re layering genetic mutations, co-mutations, expression levels, radiographs, digital pathology, and treatment outcomes to give providers a comprehensive picture," he says.

As Tempus continues to expand its offerings and impact, Dr. Cohen envisions a future where AI reshapes every aspect of healthcare, from patient interactions to drug development.

"The future is disruptive, and it's going to change incredibly fast. Fasten your seatbelts—we’re in an amazing time."